Current Clinical Trials

Breast Center of Excellence research

To inquire about the Breast Cancer Center of Excellence’s ongoing clinical trials, please reach the clinical research team on 01-350000 Ext: 5110,  7804 or 7803

For international clinical trials on Breast Cancer, please check the following link: https://clinicaltrials.gov/

Ongoing breast cancer clinical trials:

PI: Nagi Saghir

• EPIK-B3: A Phase III, multicenter, randomized, doubleblind, placebocontrolled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nabpaclitaxel in patients with advanced triple negative breast cancer

• BIO-2019-0174: A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor positive (103873) (2020- Ongoing)

• BIO-2019-054: A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (Award Number: 103815) (2019- ongoing) POSITIVE

• CLEE011F2301: A Randomized Double Blind Placebo Controlled Study of Ribociclib wth Fulvestrant for the Treatment of Postmenopausal Women with Hormone Receptor Positive,HER-2Negative Advanced Breast Cancer Who Have Received No or Only 1 Line of Prior Endocrine Treatment (Award 103130) 2016- ongoing)

• CLEE011E2301: Randomized, Double Blind, Placebo Controlled Study Of Lee01 Or Placebo In Combination With Tamoxifen &Goserelin Or A Non Steroidal Aromatase Inhibtor &Goserlin For The Treatment Of Premenopausal Women (Award 102970) (2015- Ongoing)

• Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS (Award# 104160 ; Project# 26498)

• A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study

• A Multi-Country Observational Retrospective Study to Evaluate the Prevalence of PD-L1 and its Role in Patients with TNBC Treated with Systemic Therapy.